Optipeg-A

Peginterferon alfa-2a [Pegylated Interferon alfa-2a] ·Incepta Pharmaceuticals Ltd.·SC Injection

0 views 0 reviews

Packages & prices

Pack	Price	Details
0.5 ml pre-filled syringe	৳	0.5 ml pre-filled syringe: BDT 9,800.00

Administration

Chronic hepatitis C: The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh

Chronic hepatitis B: The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh

Hepatitis C Genotype 1 & 4:

Pegylated Interferon alfa-2a Monotherapy: 180 mcg once weekly for 48 weeks
Pegylated Interferon alfa-2a dual therapy: 180 mcg once weekly for 48 weeks; Celbarin: <75 kg= (400+0+600) mg, >75 kg= (600+0+600) mg.

Hepatitis C Genotype 2 & 3:

Pegylated Interferon alfa-2a Monotherapy: 180 mcg once weekly for 48 weeks
Pegylated Interferon alfa-2a dual therapy: 180 mcg once weekly for 24 weeks; Celbarin: (400+0+400) mg.

Effects

Depression, suicide, relapse of drug abuse and bacterial infection
Flu like symptoms: Fatigue, pyrexia,
Gastrointestinal: Nausea/Vomiting, diarrhea, abdominal pain
Metabolic and Nutritional: Anorexia
Musculoskeletal: Myalgia, arthralgia
Neurological: Headache, dizziness, insomnia
Psychiatric reactions: Irritability, anxiety
Injection site reaction, skin problems, hair loss
Endocrine: Hypothyroidism

There are limited experiences of overdose. There were no serious reactions attributed to overdose. There is no specific antidote. Dialysis is not effective.

Indications

Chronic Hepatitis C: Peginterferon alfa-2a alone or in combination with Ribavirin, is indicated for the treatment of adults with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha.

Chronic Hepatitis B: Peginterferon alfa-2a is indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation.

Pharmacology

Peginterferon alfa-2a are interferon proteins bound to polyethylene glycol (PEG) molecules resulting in higher and more prolonged serum interferon concentrations. It has antiviral, antiproliferative and immune-regulating activity. Interferons are activated when it interacts with cells through high affinity cell surface receptors. The effects of this activation include the induction of gene transcription, inhibition of cellular growth, alteration of cellular differentiation, interference with oncogene expression, alteration of cell surface antigen expression, increase in phagocytic activity of macrophages and augmentation of cytotoxicity of lymphocytes for target cells.

Precautions

Patients who have failed alpha interferon treatment with or without ribavirin
Liver or other organ transplant recipients
Hepatitis B patients coinfected with HCV or HIV
Hepatitis C patients coinfected with HBV or coinfected with HIV with a CD4+ cell count < 100 cells/µL
Caution should be exercised in initiating treatment in any patient with baseline risk of severe anemia